Study guide

13.1 Acute Kidney Injury (AKI) & Chronic Kidney Disease (CKD)

NCCPA PANCE Physician Assistant Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Cardiovascular System

1.1 Hypertension (Essential & Secondary) 1.2 Coronary Artery Disease & Myocardial Infarction 1.3 Heart Failure & Cardiomyopathy 1.4 Cardiac Arrhythmias & Conduction Disorders 1.5 Valvular Heart Disease 1.6 Vascular Diseases (Aortic Aneurysm, PAD, DVT) 1.7 Congenital Heart Disease (ASD, VSD, PDA, Coarctation, Tetralogy of Fallot)

2 Chapter 2: Pulmonary System

Section 2.1: Asthma & Bronchospastic Disease Section 2.2: Chronic Obstructive Pulmonary Disease (COPD) Section 2.3: Infectious Pulmonary Disorders (Pneumonia & Tuberculosis) Section 2.4: Restrictive, Vascular & Neoplastic Pulmonary Conditions

3 Chapter 3: Gastrointestinal/Nutrition

3.1 Esophageal & Gastric Disorders (GERD, PUD) 3.2 Hepatic, Biliary & Pancreatic Disorders 3.3 Small & Large Bowel Disorders (IBD, Diverticulitis, Obstruction) 3.4 Colorectal Neoplasms & Nutritional Deficiencies

4 Chapter 4: Musculoskeletal System

Section 4.1: Rheumatologic & Autoimmune MSK Conditions (RA, Lupus, Gout, OA) Section 4.2: Infectious & Inflammatory MSK Disorders (Osteomyelitis, Septic Arthritis) Section 4.3: Bone & Joint Disorders (Fractures, Osteoporosis, Fibromyalgia) Section 4.4: Spine and Soft Tissue Pathology (Low Back Pain, Tendonitis)

5 Chapter 5: Neurologic System

Section 5.1: Cerebrovascular Disease (Stroke, TIA) Section 5.2: Seizure Disorders & Epilepsy Section 5.3: Demyelinating & Neurodegenerative Diseases Section 5.4: Headache Syndromes & Cranial Nerve Disorders

6 Chapter 6: Psychiatry/Behavioral Science

Section 6.1: Depressive and Bipolar Disorders Section 6.2: Anxiety, Trauma-Related, and Obsessive-Compulsive Disorders Section 6.3: Schizophrenia and Psychotic Disorders Section 6.4: Eating, Substance Use, and Personality Disorders

7 Chapter 7: Infectious Diseases

7.1 Viral Infections (HIV, EBV, Influenza) 7.2 Bacterial & Spirochetal Infections (Sepsis, Meningitis) 7.3 Fungal & Parasitic Infections 7.4 Tick-Borne Diseases (Lyme, Rocky Mountain Spotted Fever)

8 Chapter 8: Reproductive System

8.1 Obstetrics: Normal Pregnancy & Prenatal Care 8.2 Obstetrics: Pregnancy Complications 8.3 Gynecology: Menstruation, Menopause, PCOS, and Vaginal Infections

9 Chapter 9: Endocrine System

Section 9.1: Diabetes Mellitus & Acute Complications Section 9.2: Thyroid Disorders & Goiter Section 9.3: Adrenal & Pituitary Disorders

10 Chapter 10: Eyes, Ears, Nose, and Throat

Section 10.1: Ophthalmic Disorders (Glaucoma, Conjunctivitis, Cataracts) Section 10.2: Otic Disorders (Otitis Media/Externa, Vertigo, Labyrinthitis) Section 10.3: Nose, Sinus, and Throat Complaints (Sinusitis, Pharyngitis, Epiglottitis)

11 Chapter 11: Professional Practice

11.1 Bioethics & Legal Standards (Informed Consent, Autonomy, HIPAA) 11.2 Patient Safety, Quality Improvement, and Communication 11.3 Evidence-Based Medicine & Clinical Practice Guidelines

12 Chapter 12: Hematologic System

Section 12.1: Anemias (Microcytic, Macrocytic, Hemolytic/Sickle Cell) Section 12.2: Coagulation and Bleeding Disorders (ITP, TTP, Hemophilia, vWD) Section 12.3: Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)

13 Chapter 13: Renal System

13.1 Acute Kidney Injury (AKI) & Chronic Kidney Disease (CKD) 13.2 Acid-Base and Electrolyte Disorders 13.3 Glomerular & Tubulointerstitial Diseases

14 Chapter 14: Dermatologic System

Section 14.1: Inflammatory & Autoimmune Skin Conditions Section 14.2: Infectious Skin Conditions Section 14.3: Skin Neoplasms & Burn Management

15 Chapter 15: Genitourinary System

Section 15.1: Male Genitourinary Disorders (BPH, Prostate Cancer, Testicular Torsion, ED) Section 15.2: Urinary Incontinence, Nephrolithiasis, and GU Trauma

13.1 Acute Kidney Injury (AKI) & Chronic Kidney Disease (CKD)

Key Takeaways Explain This Topic AI

AKI is defined by KDIGO criteria as an abrupt decline in kidney function, marked by a serum creatinine rise of >= 0.3 mg/dL within 48 hours or a >= 1.5-fold increase from baseline.

Prerenal AKI results from renal hypoperfusion (e.g., dehydration, hemorrhage, sepsis) and is characterized by a BUN/Cr ratio > 20:1, FeNa < 1%, and hyaline casts; GFR improves rapidly with fluid restoration.

Intrinsic AKI from acute tubular necrosis (ATN) is marked by muddy brown granular casts, FeNa > 2%, and urine sodium > 40 mEq/L, and does not respond immediately to volume expansion.

Chronic Kidney Disease (CKD) staging is based on GFR (G1 to G5) and Albuminuria (A1 to A3), with diabetes mellitus and hypertension as the leading etiologies in the United States.

Renal osteodystrophy in CKD is driven by phosphorus retention, hypocalcemia, and decreased 1,25-dihydroxyvitamin D production, resulting in secondary hyperparathyroidism.

Last updated: July 2026

Acute Kidney Injury (AKI) & Chronic Kidney Disease (CKD)

PANCE High-Yield Focus: Renal medicine is highly tested on the PANCE, with Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD) representing core concepts. You must be able to classify AKI into prerenal, intrinsic, and postrenal types using clinical history, physical exam findings, and lab indices like the blood urea nitrogen-to-creatinine (BUN/Cr) ratio, fractional excretion of sodium (FeNa), and urine microscopy. For CKD, focus on the stages of kidney disease, cardiovascular risk reduction, and the management of complications such as renal osteodystrophy and anemia of chronic disease.

Acute Kidney Injury (AKI)

Acute Kidney Injury (AKI) is defined by the Kidney Disease: Improving Global Outcomes (KDIGO) consensus as an abrupt decline in kidney function, clinically identified by:

  • An increase in serum creatinine of >= 0.3 mg/dL within 48 hours;
  • An increase in serum creatinine to >= 1.5 times baseline within the prior 7 days;

Urine output < 0.5 mL/kg/hour for at least 6 consecutive hours.

The diagnostic workup of AKI requires classification into one of three distinct etiologic categories: prerenal, intrinsic, or postrenal.

1. Prerenal AKI (Hypoperfusion)

Prerenal AKI is the most common cause of acute renal failure in both outpatient and inpatient settings. It results from a decrease in effective renal blood flow, leading to a reduced GFR, without causing structural damage to the kidney parenchyma.

Pathophysiology and Risk Factors: Risk factors include volume depletion (vomiting, diarrhea, hemorrhage, excessive diuresis), systemic vasodilation (sepsis, anaphylaxis), and localized renal hypoperfusion (heart failure, cirrhosis, bilateral renal artery stenosis). In response to low perfusion, the kidneys activate the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system to retain water and sodium. Glomerular pressure is maintained by prostaglandin-mediated afferent arteriole vasodilation and Angiotensin II-mediated efferent arteriole vasoconstriction.

Nephrotoxic Traps: Nonsteroidal anti-inflammatory drugs (NSAIDs) block prostaglandins, causing afferent vasoconstriction. ACE inhibitors and ARBs block Angiotensin II, causing efferent vasodilation. Both drug classes can precipitate acute prerenal kidney failure in hypoperfused patients and must be held.

Diagnostics: Because the renal tubules remain functional, they aggressively reabsorb water and electrolytes.

BUN/Cr Ratio: > 20:1 (urea is passively reabsorbed along with sodium and water, whereas creatinine is not).

Fractional Excretion of Sodium (FeNa): < 1% (indicates intact sodium conservation). Use Fractional Excretion of Urea (FeUrea) < 35% if the patient is taking diuretics.

Urine Sodium (UNa): < 20 mEq/L.

Urine Osmolality: > 500 mOsm/kg (intact urinary concentrating ability).

Urine Sediment: Characterized by hyaline casts (composed of Tamm-Horsfall mucoprotein, a non-specific finding).

Clinical Management: Focuses on restoring renal perfusion. Administer intravenous isotonic crystalloids (normal saline or lactated Ringer's) for hypovolemia. Optimize cardiac output in heart failure and avoid all nephrotoxins.

2. Intrinsic AKI (Structural Damage)

Intrinsic AKI involves structural damage to the glomerular, tubular, interstitial, or vascular compartments of the kidney.

Acute Tubular Necrosis (ATN)

ATN is the most common form of intrinsic AKI, representing death of the renal tubular epithelial cells.

Etiology: Ischemic ATN is caused by prolonged, uncorrected prerenal hypoperfusion (sepsis, shock). Nephrotoxic ATN is caused by exposure to substances that are directly toxic to tubular cells.

Exogenous toxins: Aminoglycoside antibiotics (e.g., gentamicin), intravenous iodinated contrast media (contrast-induced nephropathy), amphotericin B, cisplatin, and acyclovir.

Endogenous toxins: Myoglobin (from rhabdomyolysis), hemoglobin (from hemolysis), and Bence-Jones proteins (in multiple myeloma).

Diagnostics: Damaged, necrotic tubules cannot reabsorb water, sodium, or urea.

BUN/Cr Ratio: < 15:1.

FeNa: > 2%.

Urine Sodium: > 40 mEq/L.

Urine Osmolality: < 350 mOsm/kg (urine is isosthenuric, matching serum osmolality).

Urine Sediment: Characterized by muddy brown granular casts and sloughed renal tubular epithelial cells.

Clinical Management: Supportive care, including volume management, avoidance of further nephrotoxins, and correction of electrolyte disturbances (e.g., hyperkalemia). Diuretics do not improve recovery or mortality but may help manage hypervolemia.

3. Postrenal AKI (Obstructive)

Postrenal AKI arises from mechanical obstruction of urinary outflow anywhere from the renal pelvis to the urethra.

Etiology: Benign prostatic hyperplasia (BPH) is the most common cause in elderly males. Other causes include nephrolithiasis (bilateral or in a solitary kidney), pelvic malignancies (e.g., cervical, prostate, colorectal cancer), and neurogenic bladder.

Diagnostics:

Renal Ultrasound: The initial imaging study of choice to evaluate for hydronephrosis or hydroureter.

Foley Catheterization: Diagnostic and therapeutic for bladder outlet obstruction.

Management: Relieve the obstruction. Interventions include bladder catheterization, ureteral stenting, or percutaneous nephrostomy tube placement.

Chronic Kidney Disease (CKD)

Chronic Kidney Disease is defined as kidney damage (e.g., albuminuria) or a GFR < 60 mL/min/1.73m2 persisting for >= 3 months. In the United States, diabetes mellitus is the leading cause of CKD, followed by hypertension.

KDIGO Staging Criteria

CKD staging is based on GFR categories (G1 to G5) and Albuminuria categories (A1 to A3).

  • GFR Category GFR (mL/min/1.73m2) Description
  • G1 >= 90 Normal or high
  • G2 60-89 Mildly decreased
  • G3a 45-59 Mildly to moderately decreased
  • G3b 30-44 Moderately to severely decreased
  • G4 15-29 Severely decreased
  • G5 < 15 Kidney failure (requires dialysis or transplantation)
  • Albuminuria Category Albumin-to-Creatinine Ratio (ACR) Description
  • A1 < 30 mg/g Normal to mildly increased
  • A2 30-300 mg/g Moderately increased (microalbuminuria)
  • A3 > 300 mg/g Severely increased (macroalbuminuria)
  • Pathophysiology & Management of CKD Complications

As GFR declines below 30-45 mL/min/1.73m2, the kidneys' endocrine and excretory capacities are severely compromised.

Cardiovascular Risk: Cardiovascular disease is the most common cause of death in patients with CKD, preceding progression to end-stage renal disease (ESRD). Aggressive blood pressure control (goal < 130/80 mmHg) is vital. ACE inhibitors or ARBs are first-line for patients with CKD and albuminuria (A2 or A3) because they dilate the efferent arteriole, lowering intraglomerular pressure and reducing proteinuria.

Anemia of CKD: This is typically a normocytic, normochromic anemia.

Pathophysiology: Decreased synthesis of erythropoietin (EPO) by renal peritubular interstitial cells.

Management: Exclude other causes of anemia. If iron stores are insufficient (defined as Transferrin Saturation [TSAT] < 20% or ferritin < 100 ng/mL in non-dialysis patients), oral or intravenous iron therapy is initiated first. Erythropoiesis-Stimulating Agents (ESAs, e.g., epoetin alfa, darbepoetin alfa) are indicated when hemoglobin drops < 10 g/dL. Target hemoglobin should be maintained between 10 and 11 g/dL; correcting above 11.5 g/dL is associated with an increased risk of stroke, myocardial infarction, and thromboembolic events.

Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Formerly known as renal osteodystrophy.

Pathophysiology:

Decreased glomerular filtration of phosphorus leads to hyperphosphatemia .

Elevated serum phosphorus binds free calcium, causing hypocalcemia .

Declining GFR causes a loss of renal 1-alpha-hydroxylase activity, preventing the conversion of 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D (calcitriol) . This further worsens hypocalcemia by reducing gastrointestinal calcium absorption.

Chronic hypocalcemia, hyperphosphatemia, and low calcitriol levels stimulate the parathyroid glands to hypersecrete parathyroid hormone (PTH) ( secondary hyperparathyroidism ).

High PTH levels stimulate osteoclastic activity, leading to bone resorption ( osteitis fibrosa cystica ), fractures, and calciphylaxis (painful systemic medial arterial calcification).

Management:

Dietary phosphorus restriction is the initial step.

Phosphate binders are taken with meals to limit intestinal absorption. Calcium-based binders (e.g., calcium acetate, calcium carbonate) are used when calcium levels are normal or low. Non-calcium-based binders (e.g., sevelamer, lanthanum carbonate) are preferred if the patient is hypercalcemic or has vascular calcifications.

Active Vitamin D (Calcitriol) or Vitamin D analogs (paricalcitol) are used to suppress PTH secretion.

Calcimimetics (Cinacalcet) activate calcium-sensing receptors on the parathyroid glands to inhibit PTH release.

Classic PANCE Traps & Clinical Pearls

The Urgency Dialysis Mnemonic: Memorize AEIOU for the indications for urgent hemodialysis:

A cidosis: Refractory metabolic acidosis (pH < 7.1).

E lectrolytes: Refractory hyperkalemia (K+ > 6.5 mEq/L or with ECG changes).

I ntoxications: Toxic levels of dialyzable drugs (Salicylates, Lithium, Isopropanol, Methanol, Ethylene glycol).

O verload: Volume overload refractory to diuretics (e.g., acute pulmonary edema).

U remia: Uremic complications (pericarditis, encephalopathy with asterixis, neuropathy, or bleeding).

Bilateral Renal Artery Stenosis: While ACEis and ARBs are renal-protective in proteinuric CKD, they are absolutely contraindicated in patients with bilateral renal artery stenosis. In this condition, GFR is highly dependent on Angiotensin II-mediated efferent vasoconstriction. Blocking this pathway causes an acute GFR collapse and severe prerenal AKI.